Abhinav Shukla
Chief Tech/Sci/R&D Officer chez SHATTUCK LABS, INC.
Fortune : 710 077 $ au 31/03/2024
Profil
Abhinav A.
Shukla currently works at Shattuck Labs, Inc., as Chief Technology Officer from 2021.
Dr. Shukla also formerly worked at Bristol Myers Squibb Co., as Director-Manufacturing Sciences & Technology, Amgen, Inc., as Principal Scientist, KBI Biopharma, Inc., as Senior VP-Process Development & Manufacturing from 2011 to 2018, Shire Plc, as VP & Head-Biologics Process Development in 2019, CRISPR Therapeutics AG, as Vice President-Manufacturing in 2019, and Redpin Therapeutics, Inc., as Chief Technical Operations Officer from 2020 to 2021.
Dr. Shukla received his doctorate degree from Rensselaer Polytechnic Institute and undergraduate degree and graduate degree from Indian Institute of Technology New Delhi.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SHATTUCK LABS, INC.
0,17% | 30/01/2024 | 79 427 ( 0,17% ) | 710 077 $ | 31/03/2024 |
Postes actifs de Abhinav Shukla
| Sociétés | Poste | Début |
|---|---|---|
| SHATTUCK LABS, INC. | Chief Tech/Sci/R&D Officer | 01/06/2021 |
Anciens postes connus de Abhinav Shukla
| Sociétés | Poste | Fin |
|---|---|---|
Redpin Therapeutics, Inc.
 Redpin Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Redpin Therapeutics, Inc. operates as a biotechnological platform which enables targeted regulation of neuronal activity in brain to achieve treatment and control of CNS circuit and other disorders. The company was founded by Elma S. Hawkins, Jeffrey Friedman, Scott Sternson Michael Kaplitt, Sarah Stanley and Jonathan Dordick in 2017 and is headquartered in New York, NY. | Chief Tech/Sci/R&D Officer | 01/06/2021 |
| CRISPR THERAPEUTICS AG | Corporate Officer/Principal | 01/11/2019 |
| SHIRE | Corporate Officer/Principal | 01/11/2019 |
KBI Biopharma, Inc.
 KBI Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services KBI Biopharma, Inc. provides drug development and contract manufacturing services. It helps client partners accelerate and optimize drug development and manufacturing programs by offering an extensive suite of expert development and manufacturing services. The firm offers services to global pharmaceutical and biotechnology companies, and academic and non-profit organizations. The company was founded in 1996 and is headquartered in Durham, NC. | Corporate Officer/Principal | 01/06/2018 |
| AMGEN INC. | Corporate Officer/Principal | - |
Formation de Abhinav Shukla
| Rensselaer Polytechnic Institute | Doctorate Degree |
| Indian Institute of Technology New Delhi | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| AMGEN INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| CRISPR THERAPEUTICS AG | Health Technology |
| SHATTUCK LABS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
KBI Biopharma, Inc.
KBI Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services KBI Biopharma, Inc. provides drug development and contract manufacturing services. It helps client partners accelerate and optimize drug development and manufacturing programs by offering an extensive suite of expert development and manufacturing services. The firm offers services to global pharmaceutical and biotechnology companies, and academic and non-profit organizations. The company was founded in 1996 and is headquartered in Durham, NC. | Commercial Services |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Redpin Therapeutics, Inc.
Redpin Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Redpin Therapeutics, Inc. operates as a biotechnological platform which enables targeted regulation of neuronal activity in brain to achieve treatment and control of CNS circuit and other disorders. The company was founded by Elma S. Hawkins, Jeffrey Friedman, Scott Sternson Michael Kaplitt, Sarah Stanley and Jonathan Dordick in 2017 and is headquartered in New York, NY. | Commercial Services |
